论文部分内容阅读
目的:探讨肝脾动脉栓塞术治疗肝癌伴门脉高压及脾亢的价值。材料与方法:160例患者白细胞、血小板平均值分别为2.7x10~9/L、55.6×10~9/L,121例(75.6%)食道胃底静脉曲张,全部患者在肝动脉化疗栓塞术的同时行部分脾栓塞术(PSE),其中52例行2次以上 PSE。结果:86.3%(138/160)患者术后白细胞及血小板恢复正常,2个月复查白细胞、血小板平均值分别为6.5×10~9/L、166.8×10~9/L,6个月复查为4.7×10~9/L、114.2×10~9/L,较术前明显增高,门脉高压症状减轻,肝功能改善,78.8%(126/160)病人肿瘤得到控制,75.0%(120/160)病人 AFP下降,1、2、3年生存率分别为68.1%、38.2%、20.6%。结论:肝脾动脉栓塞术治疗肝癌伴门脉高压、脾亢是一种安全有效的方法。
Objective: To investigate the value of hepatosplenic artery embolization in the treatment of liver cancer with portal hypertension and splenomegaly. Materials and Methods: The average leukocyte count and platelet count of the 160 patients were 2.7×10-9/L, 55.6×10-9/L, respectively, and 121 patients (75.6%) had esophageal gastric varices. All patients underwent hepatic arterial chemoembolization. Partial splenic embolization (PSE) was performed at the same time, 52 of whom underwent PSE. Results: The white blood cells and platelets returned to normal in 86.3% (138/160) patients. The average leukocyte count and platelet count at 2 months were 6.5×10~9/L and 166.8×10~9/L, respectively. 4.7×10~9/L and 114.2×10~9/L were significantly higher than those before surgery, the symptoms of portal hypertension were relieved, liver function was improved, and tumors were controlled in 78.8% (126/160) patients, 75.0% (120/160). The patient AFP decreased. The 1-, 2-, and 3-year survival rates were 68.1%, 38.2%, and 20.6%, respectively. Conclusion: Liver and spleen artery embolization is a safe and effective method for the treatment of liver cancer with portal hypertension and splenomegaly.